3 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Ribociclib 400mg: new trials by email Literature Review of Ribociclib 400mg trials Research Report on Ribociclib 400mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer Ribociclib 400mg, Ribociclib 600mg - Breast Cancer | Phase 1 / Phase 2 | Recruiting | Nagoya City University | 86 | 2025-10-01 | 2026-04-13 |
| Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy Ribociclib 400mg, Letrozole 2.5mg, Anastrazole 1mg - HER2 Negative Breast Cancer | Phase 2 | Recruiting | Yale University | 140 | 2025-07-09 | 2026-05-26 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer RLY-2608, Fulvestrant, Palbociclib 125mg - PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Recruiting | Relay Therapeutics, Inc. | 930 | 2021-12-08 | 2025-09-22 |
Breast Neoplasms (2)
Nagoya City University (1) · Relay Therapeutics, Inc. (1) · Yale University (1)
United States (2) · Australia (1) · France (1) · Italy (1) · Japan (1) · Spain (1)
Hiroji Iwata, MD. PhD. (1) · Jing Du (1)